Floatz logo

Nerofe

Myelodysplastic Syndrome

Immune System Key Ltdprotein_peptidePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

314 Active assets in the Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
FILGRASTIM
City of Hope Medical Center
Phase 4BB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 4BB
Cyclophosphamide
Sawa Ito, MD
Phase 4BB
Daunorubicin
OHSU Knight Cancer Institute
Phase 3BB
Fludarabine
City of Hope Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Nerofe is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
55 / 100
View asset →
ovarian cancerDormant
CCC
Indicative ·
48 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →